MED — what changed in the latest 10-Q
A section-by-section comparison of MED's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-10-26 vs the prior 10-Q · 2026-08-03
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +48 | −29 | ~7 | 34 |
| Market risk (Item 3) | Text added/removed | +40 | −27 | ~26 | 42 |
| Controls & procedures | Text added/removed | +40 | −27 | ~26 | 42 |
| Legal proceedings | Text added/removed | +40 | −27 | ~26 | 42 |
| Risk factors | Text added/removed | +40 | −27 | ~26 | 42 |
| Other information | Text added/removed | +40 | −27 | ~26 | 41 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-10-26
Medifast (“Medifast,” the “Company,” “we,” or “us”) is the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™. Designed to help address the challenges of metabolic dysfunction, the Company’s holistic approach integrates science-backed p…
The Company started 2026 by executing on its recently unveiled focus on holistic metabolic health, leveraging its extensive experience in structured weight loss coupled with recent scientific research and enhanced product offerings to address the needs of a broader metabolic health market. In July 2…
Our scientifically developed products and habit creation framework, reinforced by coaches and community support, provide proven health benefits and serve as a promising foundation to develop a comprehensive metabolic health system. We continuously innovate and build upon our scientific and clinical …
through metabolic science and human connection. Coaches provide unparalleled support along with community, nutrition, and healthy habits. In a world where health and well-being can often be a difficult and solitary journey, our comprehensive system offers intensely personalized support to individual…
Science has always been integral to Medifast’s identity. Through ongoing research and compelling data that elevate the science behind the Company’s plans and innovative products, the Company is energizing its coach community to empower individuals to take control of their metabolic health. Metabolic…
Text removed vs the prior filing · source: 10-Q · 2026-08-03
Medifast, Inc. (“Medifast,” the “Company,” “we” or “us”) is the health and wellness company known for its science-backed, comprehensive metabolic health system. In October 2025, Medifast announced its strategic transformation, unveiling its focus on holistic metabolic health. The Company started 202…
loss to address the broader metabolic health challenges impacting more than 90% of U.S. adults today. Medifast’s approach focuses on addressing the root cause of metabolic dysfunction. This strategic shift targets a larger and what is believed to be a more sustainable market, focusing on a long-term…
Our scientifically developed products and habit creation framework, reinforced by coaches and community support, provide proven health benefits and serve as a promising foundation to develop a comprehensive metabolic health system. We continuously innovate and build upon our scientific and clinical …
Metabolic health, often misunderstood or overlooked, refers to the body’s ability to efficiently convert food into energy and regulate critical bodily functions. Metabolic dysfunction is a state that can often go unnoticed, placing strain on the body’s metabolic processes and potentially leading to …
Science has always been integral to Medifast’s identity. Through ongoing research and compelling data that elevate the science behind the Company’s plans and innovative products, the Company is energizing its coach community to empower individuals to take control of their metabolic health. In July 2…
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
Text removed vs the prior filing · source: 10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
Text removed vs the prior filing · source: 10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
Text removed vs the prior filing · source: 10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
Text removed vs the prior filing · source: 10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
Other information
Text added vs the prior filing · source: 10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
Text removed vs the prior filing · source: 10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice